Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.

Ken TakahashiYosuke SetoKoutaroh OkadaShinya UematsuKen UchiboriMika TsukaharaTomoko Oh-HaraNaoya FujitaNoriko YanagitaniMakoto NishioKenichi OkuboRyohei Katayama

Published in: Thoracic cancer (2020)

ALK compound mutation was found in a clinical sample that was resistant to lorlatinib after sequential ALK-tyrosine kinase inhibitor (TKI) treatment. Ceritinib and brigatinib are potential overcoming drugs against ALK I1171S + G1269A double mutation.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
risk assessment
climate change
drug induced